◈ Nootpedia
Extended Research →
Verdict, decision matrix, deep dives, sourcing notes & full sources

Cerluten

Emerging

Khavinson-framework liver "bioregulator" peptide. | Peptide · Injectable

Aliases (2)
Liver bioregulator · Khavinson liver peptide
TYPICAL DOSE
20 mg
ROUTE
Subcutaneous injection
CYCLE
Khavinson group recommends 30-day courses 2-3×/…
STORAGE
2-6°C after reconstitution; lyophilized vial ro…
✎
Did you know? You can suggest edits to improve this compound's information.
Submitted via email — no account required.
Suggest an edit
▸ Reconstitution Lyophilized peptide

Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.

Steps
  1. 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
  2. 2 Draw the planned diluent volume into a 1 mL syringe.
  3. 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
  4. 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
  5. 5 Label vial with date reconstituted; refrigerate 2-8 °C.
  6. 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
Open dose calculator for Cerluten
▸ Overview TL;DR

Khavinson-framework liver "bioregulator" peptide. Russian-only evidence base, zero Western replication, mechanism story (peptide selectively reaches hepatocyte nuclei orally/sublingually) is biologically thin. Skip — NAC, milk thistle, and choline already cover liver protection with vastly stronger evidence.

▸ Mechanism of action

Per the Khavinson short-peptide framework (V.Kh. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology), Cerluten is claimed to be a liver-tissue-specific peptide extract that:

  1. Survives oral/sublingual administration intact (questionable for any peptide)
  2. Reaches hepatocytes selectively via tissue-specific affinity
  3. Binds nuclear DNA at gene-regulatory regions
  4. Normalizes protein synthesis in damaged or aging liver cells

Critical mechanism gaps:

  • No published structure or amino-acid sequence in Western-indexed literature
  • The "tissue-specific peptide reaches the nucleus orally" mechanism is not well-supported by general peptide pharmacology — short peptides are typically degraded in GI tract or by serum peptidases
  • Khavinson framework as a whole is contested; epithalon (the most-studied member) has ~3 small Russian trials and no successful Western replication
  • "Bioregulator" is not a recognized pharmacological class in Western medicine
▸ Pharmacokinetics No data
Pharmacokinetics data not available for this compound.
No half-life mentions found in the source notes.
▸Quality indicators6 checks
✓
White, fluffy cake
Lyophilized powder should look uniform and matte before reconstitution.
✓
Clear after reconstitution
A correctly mixed solution is fully transparent — no haze or floaters.
✓
No discoloration
Yellow or brown tints suggest oxidation or degradation. Discard.
!
Slight clumping is OK
Some fine clumping pre-reconstitution is normal for hydroscopic peptides.
✓
COA available
HPLC purity ≥98% and mass-spec confirmation per batch is the gold standard.
⚠
Endotoxin tested
<0.5 EU/mg target. Not always tested by research-chem vendors — request it.
▸ What to expect Generic
  1. 1
    Week 1
    Injection / administration protocol established. Tolerability check.
  2. 2
    Week 2-4
    Early onset of effect — subtle in most users, noticeable in responders.
  3. 3
    Week 4-8
    Peak benefit window for most peptide cycles.
  4. 4
    Week 8+
    Cycle decision point: continue, taper, or break.
▸ Side effects + safety
  • Common (>10% users): None reported. (Caveat: small sample, no controlled safety data.)
  • Less common (1-10%): Mild GI discomfort.
  • Rare-serious (<1% but worth knowing): Unknown. No long-term safety data Western-indexed.
  • Specific watch periods: N/A — too little data to define watch periods.
▸References3 sources

Khavinson VKh. "Peptides and Ageing." Neuro Endocrinol Lett 2002;23 Suppl 3:11-144. **PMID: 12374906**

2002

Foundational Khavinson framework paper covering the broad short-peptide bioregulator hypothesis under which Cerluten is positioned. Backg…

pubmed.ncbi.nlm.nih.govView →

Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology 2010;11(2):139-149. **PMID: 19830585**

2010

Khavinson group review of peptide bioregulator long-term geroprotective effects; broad framework support, no Cerluten-specific RCT data.

pubmed.ncbi.nlm.nih.govView →

Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Int J Mol Sci 2022;23(7):3552. **PMID: 35408914**

2022

In vitro mechanism work on Khavinson short peptides; broad family-level support, no Cerluten-specific in vivo translation.

pubmed.ncbi.nlm.nih.govView →
Was this helpful?
Your feedback shapes what we research deeper.
Continue: Extended Research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Cerluten
Epithalon (Epitalon / Epithalamin tetrapeptide)
WATCH-LIST
Russian peptide bioregulator (Khavinson family) — synthetic pineal-derived tetrapeptide; claimed telomerase activator
LOW-MEDIUM
Pinealon
WATCH-LIST
Russian-peptide / Khavinson short bioregulator (synthetic tripeptide, "epigenetic regulator" claim)
LOW
Cortexin
SKIP-FOR-NOW
Russian-peptide / animal-derived low-molecular-weight peptide complex (bovine cerebral cortex hydrolysate, ~1-10 kDa fraction); Khavinson-network bioregulator family
LOW
Vesugen
SKIP-FOR-NOW
Russian-peptide / Khavinson short bioregulator (synthetic tripeptide, claimed "vascular bioregulator")
LOW

More in Peptide · Injectable

31 compounds in bucket
ARA-290 (Cibinetide)
WATCH-LIST
Synthetic 11-amino-acid peptide derived from the helix-B domain of erythropoietin (EPO); innate-repair-receptor (IRR) agonist; tissue-protective peptide ("non-erythropoietic EPO derivative")
MEDIUM
BPC-157
STRONG-CANDIDATE
Synthetic pentadecapeptide (15-amino-acid fragment derived from a 62-aa "Body Protective Compound" sequence in human gastric juice)
MEDIUM
Cerebrolysin
PRIMARY-PICK
Neuropeptide preparation (porcine brain hydrolysate, neurotrophic-factor mimetic)
MEDIUM
CJC-1295
SKIP-FOR-NOW
Modified GHRH(1-29) analog with Drug Affinity Complex (DAC) for albumin conjugation; long-acting growth hormone secretagogue. (CJC-1295 "no DAC" / "Modified GRF 1-29" is the same 4-amino-acid-modified GHRH(1-29) without the MPA-lysine extension and is functionally a different drug — short half-life pulsatile GHRH analog.)
MEDIUM
Cortexin
SKIP-FOR-NOW
Russian-peptide / animal-derived low-molecular-weight peptide complex (bovine cerebral cortex hydrolysate, ~1-10 kDa fraction); Khavinson-network bioregulator family
LOW
DIHEXA
WATCH-LIST
Synthetic angiotensin-IV-derived hexapeptide / oral HGF-c-Met system "potentiator"
LOW